Back to top

Analyst Blog

Zacks Equity Research

MNKD Cancer Treatment Data Released

MNKD CELG

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, pre-clinical data on MannKind Corporation’s (MNKD - Analyst Report) IRE1α inhibitor was published in Blood, the official journal of the American Society of Hematology. IRE1α inhibitor, MKC-3946, showed potential for being developed for the treatment of multiple myeloma. Results showed that the growth of myeloma cells was inhibited without normal cells being impacted.

The study was conducted by the researchers at Dana-Farber Cancer Institute in collaboration with MannKind. MannKind’s IRE-1α inhibitor MKC-3946 may have potential applications in other indications as well such as breast, brain and pancreatic cancers, autoimmune diseases, neurodegenerative diseases and certain metabolic disorders.

Multiple myeloma is a blood cancer which is incurable and has a five-year relative survival rate of approximately 41 percent, which is the lowest among all cancers. According to MannKind, around 21,700 adults in the US would be afflicted by multiple myeloma in 2012 with approximately 10,710 people dying from the disease.

Currently available multiple myeloma treatments include Celgene Corporation’s (CELG - Analyst Report) Thalidomid and Revlimid and Takeda’s Velcade.

While we are pleased with the pre-clinical data and the potential to develop MKC-3946 for cancer, we note that the candidate is several years away from the market.

MannKind is primarily focusing on the development of its lead pipeline candidate Afrezza. Afrezza is currently in two late-stage studies - MKC-171 and MKC-175. MannKind expects to complete the trials in early 2013 and file a New Drug Application by the first half of 2013.

Currently, we have a Neutral recommendation on MannKind, which carries a Zacks #3 Rank (short-term Hold rating). We expect investor focus to remain on Afrezza.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
SKECHERS USA SKX 38.53 +4.50%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDS ENLC 36.29 +1.60%